Hidrasec Infants

Hidrasec Infants is an oral pediatric formulation containing the enkephalinase inhibitor racecadotril. Marketed in the European Union, the product is designed for infants experiencing acute diarrhea. It is presented without a specified strength, reflecting its use as a dose‑adjusted liquid preparation. The medication belongs to the antidiarrheal therapeutic class and is intended to reduce intestinal fluid loss by modulating endogenous enkephalins and improve hydration status.

Hidrasec Infants is indicated for the management of acute diarrhea in infants, helping to control excessive stool output and fluid loss.

- Reduces the volume of watery stools associated with acute gastroenteritis. - Supports rehydration efforts by decreasing intestinal secretions. - Can be used alongside oral rehydration solutions as part of standard care. - May shorten the duration of diarrheal episodes in infants. - Provides a non‑opioid option for antidiarrheal therapy in young children. - May be considered when oral rehydration alone does not sufficiently control stool output. - Can be administered under medical supervision as part of a comprehensive diarrheal management plan.

Adverse reactions to Hidrasec Infants are generally uncommon, but a range of mild to serious events have been observed in clinical practice and post‑marketing surveillance.

Common: - Mild abdominal discomfort or cramping. - Transient nausea or vomiting. - Slight increase in flatulence. - Temporary loss of appetite. - Mild headache. - Temporary changes in stool consistency (e.g., softer stools). - Slight increase in heart rate (tachycardia) in a few infants.

Serious: - Allergic skin reactions such as urticaria or rash. - Severe abdominal pain suggestive of intestinal obstruction. - Persistent vomiting leading to dehydration. - Signs of hypersensitivity including swelling of the face or lips. - Acute renal impairment in patients with pre‑existing kidney disease. - Severe dehydration unrelated to diarrhea, requiring medical attention.

When prescribing Hidrasec Infants, clinicians should consider several precautionary measures to ensure safe use in the pediatric population.

- Verify the diagnosis of acute diarrhea and exclude bacterial infections that may require antibiotics. - Assess hydration status before initiating therapy and continue oral rehydration solutions. - Use with caution in infants with known hypersensitivity to racecadotril or any excipients. - Monitor for signs of worsening diarrhea or abdominal distension. - Avoid use in children with severe renal or hepatic impairment unless directed by a specialist. - Do not exceed the recommended treatment duration without medical review.

Potential drug interactions with Hidrasec Infants are limited, but certain combinations may alter its efficacy or increase the risk of adverse effects.

Avoid: - Concomitant use of potent opioid analgesics that may mask gastrointestinal symptoms. - Co‑administration with other antidiarrheal agents such as loperamide, which could lead to excessive reduction of gut motility.

Use with caution: - Antacids containing aluminum or magnesium, which might affect oral absorption of racecadotril. - Broad‑spectrum antibiotics, as changes in gut flora could modify the clinical response. - Electrolyte‑containing rehydration solutions, requiring monitoring to avoid electrolyte imbalance. - Vitamin D supplements, because high doses may theoretically influence intestinal secretion patterns, warranting observation.